Pelmeg
pegfilgrastim
Table of contents
Overview
Pelmeg is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.
It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).
Pelmeg is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).
Pelmeg is a ‘biosimilar medicine’. This means that Pelmeg is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Pelmeg is Neulasta.
-
List item
Pelmeg : EPAR - Medicine overview (PDF/74.55 KB)
First published: 03/12/2018
EMA/653835/2018 -
-
List item
Pelmeg : EPAR - Risk-management-plan summary (PDF/98.97 KB)
First published: 03/12/2018
Last updated: 09/11/2020
Authorisation details
Product details | |
---|---|
Name |
Pelmeg
|
Agency product number |
EMEA/H/C/004700
|
Active substance |
pegfilgrastim
|
International non-proprietary name (INN) or common name |
pegfilgrastim
|
Therapeutic area (MeSH) |
Neutropenia
|
Anatomical therapeutic chemical (ATC) code |
L03AA13
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Biosimilar |
This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines. |
Publication details | |
---|---|
Marketing-authorisation holder |
Mundipharma Corporation (Ireland) Limited
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
20/11/2018
|
Contact address |
United Drug House Magna Drive |
Product information
24/02/2023 Pelmeg - EMEA/H/C/004700 - IG/1593
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunostimulants
Therapeutic indication
To reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy.